Log-in
Sign-up
Webcast
Clinical Trials
Library
Webcast
Clinical Trials
Library
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
WITHDRAWN
NCT06585969
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
0
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic Breast Cancer
ER-positive Breast Cancer
Luminal B
Her2 Enriched
Basal Like
RECRUITING
NCT05945732
DESTINY Breast Respond HER2-low Europe
1,155
Enrollment(s)
211
Study location(s)
OBSERVATIONAL (None)
Unresectable Breast Cancer
Metastatic Breast Cancer
HER2-low Expressing Breast Cancer
RECRUITING
NCT06769490
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
44
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE1)
Acute Myeloid Leukemia
RECRUITING
NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
550
Enrollment(s)
166
Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic HER2-positive Breast Cancer
ENROLLING_BY_INVITATION
NCT06250777
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
27
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
Non Small Cell Lung Cancer
COMPLETED
NCT01903694
Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
474
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE3)
Child-Pugh A Hepatocellular Carcinoma
RECRUITING
NCT07393425
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
50
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
HER2 + Breast Cancer
RECRUITING
NCT06691191
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
48
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
16
17
18
19
20